Harnessing Institutionally Developed Clinical Targeted Sequencing to Improve Patient Survival in Breast Cancer: A Seven-Year Experience
Koh J, Kim J, Woo G, Yi H, Kwon S, Seo J, Bae J, Kim J, Won J, Ryu H, Jeon Y, Lee D, Kim M, Kim T, Lee K, Kim T, Lee J, Seong M, Kim S, Lee S, Yun H, Song M, Choi J, Kim J, Im S. Harnessing Institutionally Developed Clinical Targeted Sequencing to Improve Patient Survival in Breast Cancer: A Seven-Year Experience. Cancer Research And Treatment 2024, 57: 443-456. PMID: 39164082, PMCID: PMC12016828, DOI: 10.4143/crt.2024.296.Peer-Reviewed Original ResearchConceptsNext-generation sequencingBreast cancerBC patientsHuman epidermal growth factor receptor-2 immunohistochemistryNext-generation sequencing testClinical next-generation sequencingClinical translationAmplification of CCND1Pathogenic/likely pathogenic mutationsOverall survival advantageMetastatic breast cancerNext-generation sequencing analysisPersonalized therapeutic strategiesMulti-gene testingIn situ hybridizationSequencing platformsHigher disease burdenERBB2 amplificationTarget sequenceAsian patientsPatient survivalTargeted therapyPathogenic mutationsSurvival advantagePathogenic alterations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply